一项关于三氧化二砷治疗复发难治性急性淋巴细胞白血病的II期试验。
A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia.
作者信息
Litzow Mark R, Lee Sandra, Bennett John M, Dewald Gordon W, Gallagher Robert E, Jain Vibha, Paietta Elisabeth M, Racevskis Janis, Rousey Steven R, Mazza Joseph J, Tallman Martin S
机构信息
Division of Hematology, Mayo Clinic College of Medicine, 200 First St. S.W., Rochester, MN 55905, USA.
出版信息
Haematologica. 2006 Aug;91(8):1105-8. Epub 2006 Jul 25.
We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.
我们设计了一项关于三氧化二砷（AT）治疗复发难治性急性淋巴细胞白血病（ALL）的II期试验。给药剂量为0.25mg/kg/天，静脉注射，每周5 - 7天，最长60天。11名符合条件的患者中，8例为B细胞ALL，3例为T细胞ALL，2例费城染色体阳性。治疗的中位持续时间为21天（范围7 - 28天）。1例患者死于感染。无缓解病例。10例患者死亡。中位生存期为3.2个月（范围1.2 - 4.1个月）。我们得出结论，AT对ALL治疗无效。
Zotero 插件